Preselection of Patients with High TAG-72 Antigen Expression Leads to Targeting of 94% of Known Metastatic Tumor Sites with Monoclonal Antibody I-131-CC49

References

• Colcher D, Minelli MF, Roselli M. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988; 48: 4597–4603
   PubMed Web of Science ®Google Scholar
• Stramignoni D, Bowen R, Atkinson B, Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983; 31: 543–552
   PubMed Web of Science ®Google Scholar
• Thor A, Ohuchi N, Szpak CA. The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118–3124
   PubMed Web of Science ®Google Scholar
• Colcher D, Esteban JM, Carasquillo JA. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987; 47: 1185–1189
   PubMed Web of Science ®Google Scholar
• Thor A, Gorstein F, Ohuchi N. Tumor associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986; 76: 995–1006
   PubMed Web of Science ®Google Scholar
• Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988; 48: 6811–6818
   PubMed Web of Science ®Google Scholar
• Colcher D, Esteban JM, Carasquillo JA. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47: 4218–4224
   PubMed Web of Science ®Google Scholar
• Carasquillo JA, Sugarbaker P, Colcher D. Peritoneal carcinomatosis imaging with intraperitoneal injection of 1–131 labeled B72.3 monoclonal antibody. Radiology 1988; 167: 35–40
   PubMed Web of Science ®Google Scholar
• Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990; 50: 1291–1298
   PubMed Web of Science ®Google Scholar
• Larson SM. Editorial: A model for others: A strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies tergeting and TAG-72 oncofetal antigen. Cancer Invest 1993; 11(2)235–238
   PubMed Web of Science ®Google Scholar
• Gallinger S, Reilly RM, Kirsch JC. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993; 53: 271–278
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Goldenberg H, Sharkey RN. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989; 19: 262–281
   PubMed Web of Science ®Google Scholar
• Johnson VG, Schlom J, Paterson AJ. Analysis of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Cancer Res 1986; 46: 850–857
   PubMed Web of Science ®Google Scholar
• Muraro R, Kuraki D, Wunderlich D. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988; 48: 4588–4596
   PubMed Web of Science ®Google Scholar
• Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diiphenylglycouril. Biochem Biophys Res Commun 1978; 80: 849–857
   PubMed Web of Science ®Google Scholar
• Rockoff SD, Goodenough DJ, McIntire KR. Theoretical limitations in the immunodiagnostic imaging of cancer with computed tomography and nuclear scanning. Cancer Res 1980; 40: 3054–3058
   PubMed Web of Science ®Google Scholar
• Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814s–819s, (Suppl)
   PubMed Web of Science ®Google Scholar
• Carasquillo JA, Sugarbaker P, Colcher D. Radioimmunoscintigraphy of colon cancer with iodine 131 labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29: 1022–1030
   PubMed Web of Science ®Google Scholar
• Martin EW, Carey LC. Second-look surgery for colorectal cancer. Ann Surg 1991; 124: 321–327
   Google Scholar
• Cohen AM, Martin EW, Lavery I. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991; 126: 349–352
   PubMed Web of Science ®Google Scholar
• Sickle-Santonello BJ, O'Dwyer PJ, Mojzisik CM. Radio immunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon rectum 1987; 30: 761–764
   PubMed Web of Science ®Google Scholar
• Maguire R, Pascucci V, Maroli A. Radioimaging with 111 In-CYT-103: Effect on the presurgical management of colorectal cancer patients. Proceedings of the American Society of Clinical Oncology. 1990. American Society of Clinical Oncology, Chicago, 397, (abstract)
   Google Scholar
• Esteban JM, Colcher D, Sugarbaker P. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered monoclonal antibody B72.3. Int J Cancer 1987; 39: 50–59
   PubMed Web of Science ®Google Scholar